878-P: Maximize Benefits of SGLT2 Inhibitors in People with Advanced CKD Stages with Type 2 Diabetes

Objective: SGLT2 inhibitor (SGLT2i) should be considered for people with CKD with type 2 diabetes (T2D) . Since eGFR declining speed and responsiveness to SGLT2i are different in each person, we assessed renal protective effects by individual eGFR slope analysis. Methods: A total of 75 patients with T2D with advanced CKD stage 3-4, treated by SGLT2i (empagliflozin 65% and others) were analyzed. The duration of diabetes at the time of recruitment were as follows: stage 3a (n=29) ; 11.9±5.4, stage 3b (n=28) ; 19.9±12.1, and stage 4 (n=18) ; 13.8±8.5 years. The mean of age was 70.3±12.2 year-old. GLP-1RAs was used in 41%, 64% and 44% respectively. Most rapid baseline eGFR slopes were calculated from 45.7±19.9 months before using SGLT2i, and slopes after adding SGLT2i were calculated from 39.2±11.4 months. Results: 1) In total, the initiation of SGLT2i decreased eGFR from 46.1±14.1 to 43.6±13.5ml/min/1.73m2 (P